(Q51331106)

English

Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.

scientific article published on 10 December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. (English)

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Signe Sørensen Torekov

1

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

Jens Juul Holst

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

author name string

M R Ehlers

3

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

publication date

10 December 2013

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

16

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

5

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

451-456

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12240

21 January 2018

Identifiers

10.1111/DOM.12240

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24251641

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51331106&oldid=1250853981"